Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Related MRK
Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader
Fast Money Halftime Report Final Trade From September 26 - Merck & Co., Inc., NCR Corporation And BP plc
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Merck & Co. closed on Thursday at $48.73.

Latest Ratings for MRK

DateFirmActionFromTo
Sep 2014JefferiesMaintainsHold
Aug 2014Deutsche BankInitiates Coverage onHold
Aug 2014JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters